Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 4/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.61 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 2/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.61 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.61 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194831 | 1.00 | CXCL8 (0.65) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| SCHEMBL27930873 | 0.98 | CXCL8 (0.62) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| SCHEMBL11226769 | 0.98 | CXCL8 (0.62) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| Ammonia Solution, Strong SCHEMBL28173002 | 0.98 | CXCL8 (0.62) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| Bromide SCHEMBL8119525 | 0.98 | CXCL8 (0.62) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| Hydrochloric Acid SCHEMBL2529217 | 0.98 | CXCL8 (0.62) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| Acetic Acid SCHEMBL11770944 | 0.94 | CXCL8 (0.59) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| SCHEMBL11776630 | 0.92 | CXCL8 (0.57) | CXCL8AKR1B1CTBP2TTRPTGS2 | |
| SCHEMBL2547244 | 0.84 | AKR1B1 (0.63) | CXCL8AKR1B1TTRPTGS2AKR1B10 | |
| SCHEMBL31365969 | 0.84 | CTBP2 (0.58) | CXCL8CTBP2RAB9APKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865980-A | Clopidogrel hydrogen sulfate impurity and preparation method thereof | 天方药业有限公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024254527-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-111683926-B | Compounds of formula (I) | 企业治疗学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024224093-A1 | DESMURAMYLPEPTIDE DIEESTERS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| CN-118548662-A | Substrate processing method, substrate processing apparatus, processing liquid, and processing liquid evaluation method | 株式会社斯库林集团 | 2024-08-27 | — | — | CN | disclosed |
| CN-113072551-B | Nitrogen-containing biphenyl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-117865980-A | Clopidogrel hydrogen sulfate impurity and preparation method thereof | 天方药业有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2023107597-A2 | BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-112979546-B | Butyrylcholine esterase selective inhibitor and preparation method and application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-112812113-B | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2022-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | CXCL8 1386/4885AKR1B1 1661/4885CTBP2 4787/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CXCL8 3518/4885AKR1B1 519/4885CTBP2 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.